Sort
30,917 grants matching “tumor microenvironment”
IKK<alpha> and the control of prostate cancer metastasis
$264,195Michael Karin · University Of California, San Diego · R01 · FY2010 · CA
IKK<alpha> and the control of prostate cancer metastasis
$264,195Michael Karin · University Of California, San Diego · R01 · FY2009 · CA
The role of B-cells in the anti-tumor immune response in triple negative breast cancer
$264,185Stephanie M Downs-Canner · Sloan-Kettering Inst Can Research · K08 · FY2024 · CA
The role of B-cells in the anti-tumor immune response in triple negative breast cancer
$264,185Stephanie M Downs-Canner · Sloan-Kettering Inst Can Research · K08 · FY2023 · CA
The role of B-cells in the anti-tumor immune response in triple negative breast cancer
$264,185Stephanie M Downs-Canner · Sloan-Kettering Inst Can Research · K08 · FY2022 · CA
Computational Analysis Core
$264,181Douglas A Lauffenburger · Massachusetts Institute Of Technology · U54 · FY2021 · CA
CELL MEDIATED IMMUNITY IN MAMMARY TUMOR MODELS
$264,179University Of Miami School Of Medicine · R01 · FY2000 · CA
Regulation of Adhesion and Proteolysis in Ovarian Cancer
$264,148Ernst Lengyel · University Of Chicago · R01 · FY2014 · CA
Improving T Cell Therapies for Nasopharyngeal Cancer
$264,141Helen E Heslop · Baylor College Of Medicine · P01 · FY2015 · CA
Improving T Cell Therapies for Nasopharyngeal Cancer
$264,138Helen E Heslop · Baylor College Of Medicine · P01 · FY2017 · CA
Improving T Cell Therapies for Nasopharyngeal Cancer
$264,136Helen E Heslop · Baylor College Of Medicine · P01 · FY2016 · CA
Transduction of T cells to improve migration to tumor
$264,095Patrick Hwu · University Of Tx Md Anderson Can Ctr · R01 · FY2014 · CA
Clinical Translation of a Novel Diagnostic Agent to Predict Immunotherapy Response in Solid Tumors
$264,066James F Kronauge · Cytosite Biopharma, Inc. · R44 · FY2018 · CA
IKK<alpha> and the control of prostate cancer metastasis
$264,045Michael Karin · University Of California, San Diego · R01 · FY2009 · CA
FAK and Pky2 in Determination of Glioblastoma Phenotype
$263,952Joseph C Loftus · Mayo Clinic Arizona · R01 · FY2009 · CA
The Role of Lumican in the cornea
$263,920Shukti Chakravarti · Johns Hopkins University · R01 · FY2009 · EY
Targeting Malignant Gliomas with a Novel Inhibitor of the STAT3 Pathway
$263,896Amy Beth Heimberger · University Of Tx Md Anderson Can Ctr · P50 · FY2017 · CA
Novel Strategies for Immunotherapy of Cancer
$263,871Rongfu Wang · Methodist Hospital Research Institute · R01 · FY2014 · CA
Evading Immune Escape Mechanisms in Dual-Targeted T-cell Therapy for Breast Canc
$263,862Juan Fernando Vera · Baylor College Of Medicine · P50 · FY2014 · CA
Obesity and Inflammation
$263,862Louis Simchowitz · National Institute Of Diabetes And Digestive And Kidney Diseases · Z01 · FY2008 · DK
TAM receptor inhibition in NF1-associated peripheral nerve sheath tumors
$263,856David W. Clapp · Indiana University Indianapolis · R01 · FY2023 · NS
Arkansas Integrative Metabolic Research Center
$263,813Kyle Patrick Quinn · University Of Arkansas At Fayetteville · P20 · FY2024 · GM
Angiogenin and its small RNA products in glioblastoma and brain microenvironment
$263,770Anna M. Krichevsky · Brigham And Women'S Hospital · R21 · FY2016 · NS
EAGER: A Microfluidic Device for Studying Environment-Triggered Migration of Glioblastoma Cells
$263,767Stefan H Bossmann · University Of Kansas Medical Center Research Institute Inc · · FY2021 · ENG
LIGHT for the Recognition and Eradication of Advanced Cancer
$263,760Yang-Xin Fu · University Of Chicago · P01 · FY2011 · CA